| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $6,335,277 ) |
| | 2026 | 2026 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R25CA259244 | Empowering the Next Generation of Cancer Professionals: the Fox Chase Cancer Center-University of Delaware Partnership for Undergraduate Research and Career Development | 001 | 5 | NIH | 3/2/2026 | $151,638 |
| | 2026 | 2026 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA289703 | Hepatic Tissue Integrity and Clonal Fitness: Key Factors in Controlling β-Catenin Induced Oncogenesis | 000 | 3 | NIH | 2/27/2026 | $523,854 |
| | 2026 | 2026 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA281212 | Elucidating the critical role of Wee1 in GIST | 000 | 4 | NIH | 2/27/2026 | $430,050 |
| | 2026 | 2026 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA289629 | Targeting anoctamin 6 to disrupt trogocytosis of cancer-associated fibroblasts | 000 | 2 | NIH | 2/25/2026 | $642,755 |
| | 2026 | 2026 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA262466 | Assessing DNA polymerase theta as a therapeutic target in BRCA1 mutant cancer | 000 | 5 | NIH | 2/25/2026 | $430,050 |
| | 2026 | 2026 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R37AI110985 | Regulation of hematopoiesis by ribosomal protein paralogs | 000 | 12 | NIH | 1/29/2026 | $684,005 |
| | 2026 | 2026 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01MD018511 | Neighborhood, social connectedness, and allostatic load | 001 | 4 | NIH | 2/22/2026 | $66,691 |
| | 2026 | 2026 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA282766 | Interrogating MRCK Protein Kinases in Ovarian Cancer | 000 | 3 | NIH | 2/26/2026 | $408,139 |
| | 2026 | 2026 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01MD018511 | Neighborhood, social connectedness, and allostatic load | 000 | 4 | NIH | 1/12/2026 | $600,215 |
| | 2026 | 2026 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA269975 | Small-molecule exploitation of ZBP1-driven nuclear necroptosis for cancer immunotherapy | 000 | 4 | NIH | 12/30/2025 | $683,088 |
| | 2026 | 2026 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R35GM144131 | Deciphering Networks Controlling DNA Amplification | 000 | 5 | NIH | 12/9/2025 | $420,750 |
| | 2026 | 2026 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R35GM119560 | Molecular Mechanisms Underlying Adaptor-Mediated Integrin Signaling in a Species-Specific Manner | 000 | 10 | NIH | 12/16/2025 | $433,373 |
| | 2026 | 2026 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R21CA296696 | Assessment of Efficacy and Toxicity of T3 for Medulloblastoma Treatment | 000 | 2 | NIH | 1/27/2026 | $237,809 |
| | 2026 | 2026 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01MD017675 | Reducing Urban Cervical Cancer Disparities Using a Tailored mHealth Intervention to Enhance Colposcopy Attendance | 000 | 4 | NIH | 1/26/2026 | $622,860 |
| | 2026 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA259188 | Investigating the IL-1R Pathway in Anaplastic Large Cell Lymphoma for Targeted Therapy | 000 | 5 | NIH | 2/26/2026 | $0 |
| | 2026 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01GM141513 | Designing selective kinase inhibitors via deep learning | 000 | 4 | NIH | 10/27/2025 | $0 |
| | 2026 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 000 | 56 | NIH | 12/10/2025 | $0 |
| | 2026 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R25CA259244 | Empowering the Next Generation of Cancer Professionals: the Fox Chase Cancer Center-University of Delaware Partnership for Undergraduate Research and Career Development | 000 | 4 | NIH | 12/9/2025 | $0 |
| | 2026 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | UH3HL170034 | Asian American Community Cohort and Engagement Study (ACCESS) | 000 | 3 | NIH | 1/30/2026 | $0 |
| | 2026 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | UH3HL170034 | Asian American Community Cohort and Engagement Study (ACCESS) | 000 | 3 | NIH | 1/30/2026 | $0 |
| | 2026 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | UH3HL170034 | Asian American Community Cohort and Engagement Study (ACCESS) | 000 | 3 | NIH | 1/30/2026 | $0 |
| | 2026 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | UH3HL170034 | Asian American Community Cohort and Engagement Study (ACCESS) | 000 | 3 | NIH | 1/30/2026 | $0 |
| | 2026 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | UH3HL170034 | Asian American Community Cohort and Engagement Study (ACCESS) | 000 | 3 | NIH | 1/30/2026 | $0 |
| | 2026 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R21CA289161 | NPC1 as a novel therapeutic target in ccRCC | 000 | 2 | NIH | 1/29/2026 | $0 |
| | 2026 | 2024 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01AI135025 | Mechanism, Function, and Exploitation of Influenza A Virus-Activated Cell Death | 000 | 8 | NIH | 1/22/2026 | $0 |
| | 2026 | 2023 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | P01AI102853 | Molecular basis of γδ T lineage specification | 000 | 10 | NIH | 1/20/2026 | $0 |
| | 2026 | 2023 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01AI144400 | Targeting RIPK3 in Flu-Associated Lung Injury | 000 | 5 | NIH | 1/27/2026 | $0 |
|
| Issue Date FY: 2025 ( Subtotal = $30,772,944 ) (Continued on the next page) |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R21CA292276 | Exploring the Neuroprotective Potential of CBD in Preventing Oxaliplatin-Induced Neuropathy: A Prospective Study | 000 | 1 | NIH | 7/30/2025 | $429,162 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R21CA289161 | NPC1 as a novel therapeutic target in ccRCC | 001 | 2 | NIH | 5/22/2025 | $26,367 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R21CA289161 | NPC1 as a novel therapeutic target in ccRCC | 000 | 2 | NIH | 3/4/2025 | $237,303 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R21CA296696 | Assessment of Efficacy and Toxicity of T3 for Medulloblastoma Treatment | 000 | 1 | NIH | 1/28/2025 | $219,351 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | T32CA278766 | Training Grant in Precision Cancer Control | 000 | 3 | NIH | 8/20/2025 | $281,315 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R37CA283552 | Targeting DHX9 to trigger viral mimicry and immunotherapy responsiveness in Small Cell Lung Cancer (SCLC) | 000 | 2 | NIH | 8/6/2025 | $649,679 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | UH3CA271230 | Validation of blood-based predictive biomarkers of therapeutic response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer | 000 | 4 | NIH | 5/13/2025 | $470,000 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | U01CA260369 | Optimization of urinary DNA deep sequencing tests to enhance clinical staging of bladder cancer patients | 000 | 5 | NIH | 8/8/2025 | $422,144 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R03CA286669 | Divergent Functions of ERK2 Substrate Binding Domains in Pathogenesis of KRAS-Driven Pancreatic Cancer | 000 | 2 | NIH | 11/14/2024 | $94,000 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA282766 | Interrogating MRCK Protein Kinases in Ovarian Cancer | 000 | 2 | NIH | 3/4/2025 | $406,720 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R00DK128602 | Defining the molecular basis controlling hematopoietic stem cell symmetric and asymmetric divisions | 001 | 4 | NIH | 8/4/2025 | $249,000 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01MD017675 | Reducing Urban Cervical Cancer Disparities Using a Tailored mHealth Intervention to Enhance Colposcopy Attendance | 000 | 3 | NIH | 12/17/2024 | $624,082 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01MD017675 | Reducing Urban Cervical Cancer Disparities Using a Tailored mHealth Intervention to Enhance Colposcopy Attendance | 001 | 3 | NIH | 8/12/2025 | $69,341 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R00CA263017 | The role of MER/PROS1 in promoting stromal induced emergence from metastatic melanoma dormancy | 001 | 4 | NIH | 5/29/2025 | $24,900 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R00CA263017 | The role of MER/PROS1 in promoting stromal induced emergence from metastatic melanoma dormancy | 000 | 4 | NIH | 4/23/2025 | $224,100 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA276273 | Fibroblasts Support the Growth of Brain Metastasis by Rendering Cancer Cells Resistant to Chemotherapy and Inducing Immunosuppression in Tumor Microenvironment | 000 | 3 | NIH | 6/3/2025 | $412,500 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R25CA288297 | Addressing the Training Gap in Oncology on Sexual Health: Development of the Sexual Health Integrative Fellowship Training (SHIFT) Course for Hematology-Oncology Fellows | 000 | 2 | NIH | 5/13/2025 | $161,299 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA271915 | Targeting the BCL2 immune checkpoint to enhance the immunostimulatory effects of radiation in breast cancer | 003 | 4 | NIH | 7/10/2025 | $779,894 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | U54CA272686 | Cancer Prevention-Interception Targeted Agent Discovery Program at Fox Chase Cancer Center | 000 | 4 | NIH | 9/11/2025 | $1,431,641 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R03CA292552 | Pilot Studies of NN-01-195, a New Tumor-Targeted AURKA Inhibitor | 000 | 1 | NIH | 6/23/2025 | $186,000 |
| | 2025 | 2025 | THE INSTITUTE FOR CANCER RESEARCH | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2434 | PHILADELPHIA | USA | R01CA269975 | Small-molecule exploitation of ZBP1-driven nuclear necroptosis for cancer immunotherapy | 001 | 3 | NIH | 6/12/2025 | $75,897 |
|
